Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia.

British journal of haematology - 1 Feb 2007

Bolufer Pascual, Collado Maria, Barragan Eva, Calasanz María-José, Colomer Dolors, Tormo Mar, González Marcos, Brunet Salut, Batlle Montserrat, Cervera José, Sanz Miguel-Angel

Abstract excerpt

Therapy-related acute myeloid leukaemia/myelodysplastic syndrome (t-AML/t-MDS) results from an impaired ability to detoxify chemotherapeutic drugs or repair drug-induced genetic damage caused by genetic polymorphisms in enzymes involved in the metabolism of drugs. We analysed the prevalence of genetic polymorphisms of CYP1A1*2A(T6235C), CYP2E1*5B(C-1019T), CYP3A4*1B(A-290G), del{GSTT1}, del{GSTM1}, NQO1*2(C609T),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Disease
Share to Cytochrome P-450 CYP1A1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glutathione Transferase

Share to Inactivation, Metabolic

Share to Leukemia, Myeloid

Share to Myelodysplastic Syndromes

Share to NAD(P)H Dehydrogenase (Quinone)

Share to Neoplasm Proteins

Source

Identifiers

PMID: 17367411
DOI: 10.1111/j.1365-2141.2006.06469.x

Genes

NQO1
GSTT1
GSTM1
MTHFR
TYMS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia.PMID 17367411Read ↗

Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients.Semantic proximity Read ↗

Influence of DNA damage and repair upon the risk of treatment related leukemia.Semantic proximity Read ↗

Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia.Semantic proximity Read ↗

MDR-1 and GST polymorphisms are involved in myelodysplasia progression.Semantic proximity Read ↗

The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes.Semantic proximity Read ↗

Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression.Semantic proximity Read ↗

Genetic predisposition and treatment-related leukemia.Semantic proximity Read ↗

Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia.Semantic proximity Read ↗

CYP2B6 gene single nucleotide polymorphisms and leukemia susceptibility.Semantic proximity Read ↗

Polymorphisms of CYP1A1 and glutathione S-transferase and susceptibility to adult acute myeloid leukemia.Semantic proximity Read ↗

The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia.Semantic proximity Read ↗

Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.